A Phase I, Open Label, Multicenter, Dose-escalation Study of HDM201 in Adult Patients With Advanced Solid and Hematological Tumors Characterized by Wild-type TP53
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Siremadlin (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis; Novartis Pharmaceuticals
- 23 Oct 2019 Planned End Date changed from 23 Jul 2019 to 21 Jul 2020.
- 27 Nov 2018 Planned End Date changed from 17 Oct 2018 to 23 Jul 2019.
- 01 Oct 2018 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History